當(dāng)前位置: 首頁 - 產(chǎn)品目錄 - 小分子抑制劑
Rapamycin (AY 22989, Sirolimus, RAPA,NSC 226080, Rapamune?)雷帕霉素
貨號 | IPA1021 | 售價(jià)(元) | 596 |
規(guī)格 | 10mg | CAS號 | 53123-88-9 |
- 產(chǎn)品簡介
- 相關(guān)產(chǎn)品
貨號
名稱
規(guī)格
價(jià)格
IPA1021-0010MG
Rapamycin (Sirolimus)
10 mg
596
IPA1021-0050MG
Rapamycin (Sirolimus)
50mg
1547
IPA1021-0100MG
Rapamycin (Sirolimus)
100mg
2095
IPA1021-0500MG
Rapamycin (Sirolimus)
500mg
5357
IPA1021-0001G
Rapamycin (Sirolimus)
1g
9886
IPA1021-0002G
Rapamycin (Sirolimus)
2g
17966
IPA1021-0005G
Rapamycin (Sirolimus)
5g
33946
IPA1021-0010G
Rapamycin (Sirolimus)
10g
63126
產(chǎn)品簡介:
Rapamycin曾經(jīng)被用作抗真菌抗生素。它通過抑制T細(xì)胞的激活和增殖來發(fā)揮免疫抑制作用。Rapamycin結(jié)合FK結(jié)合蛋白12(FKBP12)形成Rapamycin-FKBP12復(fù)合物,可以抑制mTOR。在HEK293細(xì)胞中,Rapamycin是一種有效而特異性的mTOR抑制劑,其IC50為0.1 nM。Rapamycin結(jié)合FKBP12并特異性地作為mTORC1的變構(gòu)抑制劑。
在所有測試的細(xì)胞系(A549、SPC-A-1、95D和NCI-H446細(xì)胞)中,拉帕霉素(12.5-100 nM;24小時)治療以劑量依賴性方式對肺癌細(xì)胞增殖產(chǎn)生適度的抑制作用,在100 nM時實(shí)現(xiàn)約30-40%的細(xì)胞增殖減少,而在12.5 nM時僅有約10%的減少。拉帕霉素不僅能有效地抑制增殖,還能以劑量依賴性方式誘導(dǎo)LEC的凋亡,在HGF管理下通過抑制AKT/mTOR、ERK和JAK2/STAT3信號分子的磷酸化來促進(jìn)LEC的凋亡。
在Ndufs4 - / -小鼠中,雷帕霉素減少了神經(jīng)疾病。在接受雷帕霉素治療的敲除小鼠中,在P35后的每個年齡點(diǎn)上表現(xiàn)出神經(jīng)癥狀的小鼠比例大大降低,并且其中約有一半的小鼠在死亡前從未顯示出明顯的神經(jīng)疾病跡象[2]。單用雷帕霉素具有適度抑制作用。然而,二甲雙胍和雷帕霉素聯(lián)合使用與對照組、單用雷帕霉素組和單用二甲雙胍組相比,能夠顯著增強(qiáng)腫瘤生長的抑制作用[8]。細(xì)胞培養(yǎng)中使用雷帕霉素可顯著抑制c-Myc調(diào)節(jié)基因表達(dá)。在體內(nèi)移植模型下,雷帕霉素通過降低STAT3和c-Myc表達(dá)來抑制肝細(xì)胞癌腫瘤生長[9]。
產(chǎn)品性質(zhì):
Cas No.:53123-88-9
別名:雷帕霉素; 西羅莫司; Sirolimus; AY-22989
Canonical SMILES: O[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H](CC([C@H](C)/C=C(C)/[C@H]([C@@H](OC)C([C@@H](C[C@@H](/C=C/C=C/C=C(C)/[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](C(C(N3[C@H]4CCCC3)=O)=O)(O)O2)C)C)=O)O)=O)OC4=O)CC1
分子式;C51H79NO13
分子量:914.18
溶解度:≥ 45.709mg/mL in DMSO, ≥ 58.9 mg/mL in EtOH with ultrasonic
儲存條件:Desiccate at -20°C
注意事項(xiàng):
為了您的安全和健康,請穿實(shí)驗(yàn)服并戴一次性手套操作。
References:
[1]: Tian F, Dong L, et,al. Rapamycin-Induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathways. Int J Mol Sci. 2014 Aug 11;15(8):13833-48. doi: 10.3390/ijms150813833. PMID: 25116684; PMCID: PMC4159827.
[2]: Johnson SC, Yanos ME, et,al. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science. 2013 Dec 20;342(6165):1524-8. doi: 10.1126/science.1244360. Epub 2013 Nov 14. PMID: 24231806; PMCID: PMC4055856.
[3]: Sehgal SN, Baker H, et,al. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 1975 Oct;28(10):727-32. doi: 10.7164/antibiotics.28.727. PMID: 1102509.
[4]: Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998 Jul;31(5):335-40. doi: 10.1016/s0009-9120(98)00045-9. PMID: 9721431.
[5]: Edwards SR, Wandless TJ. The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem. 2007 May 4;282(18):13395-401. doi: 10.1074/jbc.M700498200. Epub 2007 Mar 9. PMID: 17350953; PMCID: PMC3763840.
[6]: Rangaraju S, Verrier JD, et,al. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice. J Neurosci. 2010 Aug 25;30(34):11388-97. doi: 10.1523/JNEUROSCI.1356-10.2010. PMID: 20739560; PMCID: PMC3478092.
[7]: Niu H, Wang J, et,al. Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res. 2011 Mar 10;30(1):28. doi: 10.1186/1756-9966-30-28. PMID: 21392382; PMCID: PMC3065416.
[8]: Zhang JW, Zhao F, et,al. Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo. Oncol Lett. 2018 Feb;15(2):1811-1816. doi: 10.3892/ol.2017.7444. Epub 2017 Nov 20. PMID: 29434877; PMCID: PMC5774390.
[9]: Sun L, Yan Y, et,al. Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth. Cell Chem Biol. 2022 Mar 17;29(3):373-385.e6. doi: 10.1016/j.chembiol.2021.10.006. Epub 2021 Oct 26. PMID: 34706270.